A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT).
A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT).
复制标题
一种基于血清的新型生物标志物组具有补充能力，可以通过低剂量 CT (LDCT) 排除早期肺癌
DOI：
10.18632/oncotarget.17477
复制
发表时间：
2017-07-11
期刊：
影响因子：
--
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Wang X;Zhi X;Yang Z;Tian H;Li Y;Li M;Zhao W;Zhang C;Wang T;Liu J;Shen D;Zheng C;Zhao D;Yang S;Qi J;Xin H;Stojadinovic A;Avital I;Lee LJ;Rao J;Zhang W
低剂量计算机断层扫描 (LDCT) 已被证明可以提高肺癌的早期发现率和高危人群的死亡率，然而，这受到对重度吸烟者的专门覆盖和高假阳性率的限制。在这里，我们的目标是研究一种用于肺癌早期检测的新型生物标志物，并进一步扩展到集中高危受试者，以提高 LDCT 的特异性和覆盖范围。我们在训练和验证队列中对肺癌和健康对照进行了回顾性盲法评估。单独评估巨噬细胞抑制性细胞因子 1 (MIC-1) 和组合。我们的数据显示，MIC-1对肺癌诊断和早期诊断的敏感性分别为72.2%和67.1%，特异性为96.6%，显着高于Cyfra21-1、NSE CA125、CEA和SCC。 MIC-1、Cyfra21-1、CA125和CEA组合的特异性为90%，为肺癌早期诊断提供了89.5%的敏感性，可用于集中高危受试者进行进一步的LDCT筛查。我们得出结论，MIC-1在早期肺癌诊断方面具有强大的能力。 MIC-1、Cyfra21-1、CA125和CEA算法组合可用于细化高危受试者的预选标准，从而可能促进LDCT筛查的广泛实施。
Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.
登录
查看更多内容
影响因子：
6.5
作者：
Boyle, Glen M.;Pedley, Julie;Parsons, Peter G.
通讯作者：
Parsons, Peter G.
影响因子：
168.9
作者：
Hiley, Crispin T.;Le Quesne, John;Swanton, Charles
通讯作者：
Swanton, Charles
影响因子：
45.3
作者：
Qiu, Ji;Choi, Gina;Hanash, Samir M.
通讯作者：
Hanash, Samir M.
影响因子：
4.8
作者：
Jin, Young-June;Lee, Jeong-Hyung;Lee, Hansoo
通讯作者：
Lee, Hansoo
影响因子：
20.4
作者：
Goldstraw, Peter;Crowley, John;Sobin, Leslie
通讯作者：
Sobin, Leslie